A Korea-based investment firm manages several funds that focus primarily on the small- and mid-cap market in Korea, with around $500M AUM. Recently, the firm has closed a biotech-focused fund that will invest in global start-ups. The firm’s size of investment will depend on the stage of the company and will actively engage in follow-on investments as well. The firm actively seeks global opportunities.

The firm invests broadly across therapeutics, medical devices, and diagnostics, with the strongest interest in therapeutics. The firm is open to all types of modalities and is most interested in oncology and immunology indications as well as liver diseases such as NASH.

The firm seeks management teams with strong scientific expertise and experienced management teams. The firm may act as either a lead or co-investor and will not require a board seat post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital/private equity firm based in Shanghai, China. The firm manages both US and RMB denominated funds. The firm invests in Series A rounds at $1-2M, though its sweet spot is investing $10-15M in Series B/C rounds. The firm works closely with local provincial Chinese governments, allowing them the ability to bring technology successfully into the Chinese market. The firm will generally not invest in the seed stage, and seeks opportunities globally.

The firm invests in pharmaceuticals and Class II (510k) medical devices, including an interest in 505(b)(2) repurposed compounds, as well as healthcare-related industries. The firm is interested in all therapeutic areas and in early to mid development stage companies. The firm focuses on unmet medical needs with a China market potential.

The firm does not have management team requirements. The firm will typically take a board seat post-investment, and has the capability to lead and co-invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with offices in USA and Canada is considering opportunities for investment out its third, most recent fund. The firm leads or co-leads seed investments, typically in the $500K-$1.5M range, in seed – small A rounds, and will provide additional capital to portfolio companies of up to $8M from the primary fund and up to an additional $8M from the LP co-investment fund, over the life of the investment. The firm looks to make 3-5 investments per year.

The firm has invested in a variety of med-tech companies including a company with a drug delivery platform technology and a range of digital health companies. Moving forward the firm will be more focused on diagnostics, drug delivery and platform technologies capable of generating re-purposed drugs – emphasis placed on short sales cycles and de-risked assets. The firm is agnostic in regards to therapeutic type and will consider large and small molecules as well as re-purposed or biosimilar assets and platform technologies. The firm prefers to invest early in a therapeutic’s life cycle, typically in preclinical or phase I, and is opportunistic in terms of indication.

The firm only considers companies with experienced management teams, and requires a board seat with every investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A global venture capital firm based in Menlo Park, California is investing from a fund of over $600 million. The firm focuses on making equity investments into the life science and technology spaces from seed to late venture stage. The investment size is varied, and typically it ranges from $1 million to $20 million. The firm will invest in companies based in the US, India and Israel.

The firm is currently looking for new opportunities in the Biotech Therapeutics, Medical Devices and Healthcare IT sectors. The firm will also consider Diagnostics, but that will not be its focus. For Therapeutics and Medical Devices, the firm is extremely opportunistic in terms of subsectors and indications. The firm is interested in companies targeting orphan diseases. The firm is generally looking for companies in the clinical stage of development, but it also considers preclinical companies one or two years from clinics, as well as companies near commercial stages dependent on the case.

The firm primarily invests in private companies, and considers pre-revenue companies. The firm doesn’t have specific requirements for company’s management team or revenue.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A large Japan-based conglomerate has businesses in several industries including life sciences and chemicals, and invests in and partners with strategically relevant startups via a corporate venture group.  The firm is open to global opportunities and is geography and stage agnostic.

Healthcare/Medical is one of the major focus areas of the firm’s investments. The corporate venture capital arm is interested therapeutics solutions such as solutions beyond the pill (digital therapeutics) and around the pill (delivery systems etc). Therapeutics areas of interest are CNS, Autoimmune diseases, metabolic diseases, regenerative medicine, Aging related solutions and Vaccines. The corporate venture capital arm is also interested in diagnostics solutions based on genomics, metagenomics, metabolomics, healthcare ICT (biosensors etc), and medical big data. Furthermore, medical devices for wound care, bone cement and hospital related infection treatment is also is an area of interest and is open to all classes of medical devices including 510k and PMA.

The corporate venture capital arm has a close, collaborative relationship with the parent company and its life science businesses and can also present opportunities to other relevant branches as appropriate.  The firm is a flexible investor and does not require companies to have a Japan-centric angle. For medical device & digital therapeutics opportunities, the group does prefer technologies with strong promise in the US market.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A global investor, exclusively focused on the development of oncology therapies, makes selective investments in early-stage drug development companies targeting cancer therapies that can bring solid proof of concept to the table. Typically, the firm invests in incorporated companies from late seed stage to early series B. The investment size will vary, and it can range from 3 to 10 million dollars with the possibility of investing lower amounts for seed stage companies. The firm may make 3-4 investments in the next year, depending on the opportunity. The firm has no geographic restriction and is actively seeking new investment opportunities across the globe.

In the life sciences, the firm is currently seeking new investments targeting the development of oncology therapies, and is open to all types of therapeutic modalities and all indications within the oncology space, including platform technology that has a lead oncology therapeutic product. The firm will typically not invest in medical devices or diagnostics, unless as companion to a therapeutic solution. Project will be evaluated on solid preclinical proof-of-concept (late preclinical stage/pre-IND or early clinical), and will often fund the companies at least up to human proof-of-concept (clinical Phase Ib – Phase IIa).

The firm only invests in private companies with experienced management teams and breakthrough potential. The firm most often takes the responsibility to be lead investor, alone or in syndicate as the opportunity demands, and wants to be actively involved in the successful development and growth of the portfolio companies. To this end, the firm has several experts in oncology, intellectual property and drug development on the investment team and available to the portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm is investing out of their second fund of over $200 million.  The firm invests via relationships with universities, and also in external startups that are not from these partnerships.  The firm typically makes initial investments of $1M-$5M and allocates up to $10M over the life of the investment. The firm usually invests in Series A rounds and beyond, but only participates as a part of a syndicate where a lead investor has already been identified. Further, the firm only invests alongside other institutional capital.

Though the firm does not have a strict mandate in terms of subsector or indication, therapeutics for oncology, cardiovascular, anti-inflammatories, and ophthalmology drugs have historically done well and are favored by the investment team. In addition to therapeutics, the firm will consider diagnostics and medical devices, but has not been active in these sectors.

The firm prefers an experienced management team with a successful track record, and primarily invests in U.S. and Canadian companies. The firm does not typically seek a board seat along with an investment, but may take an observer seat in the event the company’s management team is inexperienced.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.